U.S. FDA Assessing Capability To Amplify Surveillance Of Indian, Chinese OTC Manufacturers - PharmAsia Summit
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is gathering information to sharpen its risk-assessment approach and determine inspection priorities for nutraceuticals and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less-stringent oversight.